Next Article in Journal
Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units
Next Article in Special Issue
Humoral Response of Buffaloes to a Recombinant Vaccine against Botulism Serotypes C and D
Previous Article in Journal / Special Issue
Vaccines against Botulism
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Toxins 2017, 9(9), 269; doi:10.3390/toxins9090269

Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism

1
US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
2
Ke’aki Technologies LLC, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
3
Office of the Chief Scientist, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
4
Clinical Research Management, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21707, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Jianlong Lou and James D. Marks
Received: 19 July 2017 / Revised: 29 August 2017 / Accepted: 30 August 2017 / Published: 3 September 2017
(This article belongs to the Special Issue Botulinum Neurotoxins Antibody and Vaccine)
View Full-Text   |   Download PDF [915 KB, uploaded 4 September 2017]   |  

Abstract

There are few available medical countermeasures against botulism and the discontinuation of the pentavalent botulinum toxoid vaccine by the Centers for Disease Control and Prevention in 2011 has resulted in the need for a safe and effective prophylactic alternative. Advances in genetic engineering have resulted in subsequent vaccine efforts being primarily focused on the production of highly purified recombinant protein antigens representing one or more domains of the botulinum neurotoxin. Recombinant subunit vaccines based on the carboxy one-third of the toxin (Hc) developed in our lab against serotypes A-F have been shown to be safe and effective. However, in response to the identification of an ever increasing number of BoNT subtypes with significant amino acid heterogeneity, we have developed catalytically inactive BoNT holoproteins (ciBoNT HPs) in an attempt to elicit greater protective immunity to address these toxin variants. Here we report the production of ciBoNT/B1 HP, ciBoNT/C1 HP, ciBoNT/E1 HP and ciBoNT/F1 HP and compare the immunological and protective abilities of ciBoNT HPs and BoNT/A Hc, BoNT/B Hc, BoNT/C Hc, BoNT/E Hc and BoNT/F Hc vaccines when challenged with homologous and heterologous toxins. Our results suggest the ciBoNT HP vaccines exhibit superior potency after single vaccinations but multiple vaccinations with BoNT/Hc antigens resulted in increased survival rates at the toxin challenge levels used. View Full-Text
Keywords: Clostridium botulinum; botulinum neurotoxin (BoNT); vaccine; catalytically inactive BoNT holoprotein (ciBoNT HP); BoNT subtype toxin; BoNT mosaic toxin. Clostridium botulinum; botulinum neurotoxin (BoNT); vaccine; catalytically inactive BoNT holoprotein (ciBoNT HP); BoNT subtype toxin; BoNT mosaic toxin.
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Webb, R.P.; Smith, T.J.; Smith, L.A.; Wright, P.M.; Guernieri, R.L.; Brown, J.L.; Skerry, J.C. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins 2017, 9, 269.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top